3 research outputs found
HEPATITIS C IN TRANSFUSION MEDICINE
SAŽETAK
Najnovije procjene upuÄuju na to da se svjetska prevalencija anti-HCV reaktivnosti kreÄe u Å”iroku rasponu, i to od 0,1% u razvijenim zemljama do 13,6% u sjevernoj Africi. U Europi prevalencija se kreÄe od 0,1% do najviÅ”e 4,9% u pojedinim zemljama istoÄne Europe. EpidemioloÅ”ka istraživanja predviÄaju da je približno 170 milijuna ljudi u svijetu kroniÄno inficirano hepatitis C virusom (HCV). Na osnovi preliminarnih testiranja opÄe populacije i prema procjenama, Hrvatska je svrstana u zemlje s nižom HCV prevalencijom (1% ā 2%), te incidencijom od 0,005%. KroniÄna infekcija
HCV-om sve je važniji javnozdravstveni problem, poglavito kada se radi o dobrovoljnim davateljima krvi kao moguÄim izvorima zaraze. ZadaÄa je suvremene transfuziologije lijeÄiti bolesnika sigurnim i kvalitetnim krvnim pripravcima, a postojeÄi ostatni rizik za infekciju krvlju prenosivim bolestima, svesti na najmanju mjeru. U Hrvatskoj sva se darivanja krvi obvezno testiraju na HIV, HCV, HBV i sifilis. Poslijetransfuzijski hepatitis C (PTHC) jest krvlju prenosiva bolest, te je unatoÄ obveznu anti-HCV testiranju krvi, joÅ” uvijek moguÄa komplikacija transfuzijskoga lijeÄenja u nas i u svijetu. U zemljama zapadne Europe rizik za prijenos HCV-a
krvlju i krvnim pripravcima kreÄe se u prosjeku od 1:400.000 do 1:800.000. Razloga je tomu viÅ”e: od nepostojanja simptoma i kliniÄkih znakova hepatitisa C u davatelja koji se nalazi u fazi inkubacije, nepostojanja idealnoga testa kojim bi se otkrili mnogobrojni podtipovi HCV virusa, te ā iako u malomu postotku, postojanje seronegativnih trajnih nositelja virusa koji su doživotni kliconoÅ”e.SUMMARY
Latest estimates indicate that world prevalence of anti-HCV reactivity spans widely from 0.1% in developed country to 13,6% in north Africa, while in Europe prevalence ranges from 0.1% to 4.9% in some eastern European countries. Epidemiological studies show, around 170 million people in world to be chronically infected with hepatitis C virus (HCV). Preliminary testing
of general population and according to the estimates, Croatia has classified within countries with HCV prevalence of 1%ā2%, and incidence rate of 0.005%. Chronic HCV infection represents increasingly significant public health problem, especially when we take in consideration blood donors as a possible source of infection. Modern transfusion medicine has an assignment
to treat patients with safe and quality blood preparations while minimizing risk of infection with blood transmitted diseases. In Croatia all blood donations are mandatory tested for HIV, HCV, HBV and syphilis. Although posttransfusion hepatitis C (PTHC) is only one of the possible infections transmitted by blood, there is no reason to be more concern than in other countries of Western Europe, where risk of HCV transmission through blood and blood preparations averages
from 1:400.000 to 1:800.000. Despite blood testing PTHC is still possible complication of transfusion treatments in Croatia and worldwide. Reasons for that are absence of symptoms and clinical signs of hepatitis C in incubation period of infected blood donors, absence of ideal test who would detect all cases of infected bloo
Hepatitis C U Transfuzijskoj Medicini
Latest estimates indicate that world prevalence of anti-HCV reactivity
spans widely from 0.1% in developed country to 13,6% in north Africa,
while in Europe prevalence ranges from 0.1% to 4.9% in some eastern
European countries. Epidemiological studies show, around 170 million
people in world to be chronically infected with hepatitis C virus
(HCV). Preliminary testing of general population and according to the
estimates, Croatia has classified within countries with HCV prevalence
of 1%ā2%, and incidence rate of 0.005%. Chronic HCV infection
represents increasingly significant public health problem, especially
when we take in consideration blood donors as a possible source of
infection. Modern transfusion medicine has an assignment to treat
patients with safe and quality blood preparations while minimizing risk
of infection with blood transmitted diseases. In Croatia all blood
donations are mandatory tested for HIV, HCV, HBV and syphilis. Although
posttransfusion hepatitis C (PTHC) is only one of the possible
infections transmitted by blood, there is no reason to be more concern
than in other countries of Western Europe, where risk of HCV
transmission through blood and blood preparations averages from
1:400.000 to 1:800.000. Despite blood testing PTHC is still possible
complication of transfusion treatments in Croatia and worldwide.
Reasons for that are absence of symptoms and clinical signs of
hepatitis C in incubation period of infected blood donors, absence of
ideal test who would detect all cases of infected bloodNajnovije procjene upuÄuju na to da se svjetska prevalencija
anti-HCV reaktivnosti kreÄe u Å”iroku rasponu, i to od 0,1% u
razvijenim zemljama do 13,6% u sjevernoj Africi. U Europi prevalencija
se kreÄe od 0,1% do najviÅ”e 4,9% u pojedinim zemljama
istoÄne Europe. EpidemioloÅ”ka istraživanja
predviÄaju da je približno 170 milijuna ljudi u svijetu
kroniÄno inficirano hepatitis C virusom (HCV). Na osnovi
preliminarnih testiranja opÄe populacije i prema procjenama,
Hrvatska je svrstana u zemlje s nižom HCV prevalencijom (1%
ā 2%), te incidencijom od 0,005%. KroniÄna infekcija HCV-om
sve je važniji javnozdravstveni problem, poglavito kada se radi o
dobrovoljnim davateljima krvi kao moguÄim izvorima zaraze.
ZadaÄa je suvremene transfuziologije lijeÄiti bolesnika
sigurnim i kvalitetnim krvnim pripravcima, a postojeÄi ostatni
rizik za infekciju krvlju prenosivim bolestima, svesti na najmanju
mjeru. U Hrvatskoj sva se darivanja krvi obvezno testiraju na HIV, HCV,
HBV i sifilis. Poslijetransfuzijski hepatitis C (PTHC) jest krvlju
prenosiva bolest, te je unatoÄ obveznu anti-HCV testiranju krvi,
joÅ” uvijek moguÄa komplikacija transfuzijskoga lijeÄenja
u nas i u svijetu. U zemljama zapadne Europe rizik za prijenos HCV-a
krvlju i krvnim pripravcima kreÄe se u prosjeku od 1:400.000 do
1:800.000. Razloga je tomu viŔe: od nepostojanja simptoma i
kliniÄkih znakova hepatitisa C u davatelja koji se nalazi u fazi
inkubacije, nepostojanja idealnoga testa kojim bi se otkrili
mnogobrojni podtipovi HCV virusa, te ā iako u malomu postotku,
postojanje seronegativnih trajnih nositelja virusa koji su
doživotni kliconoŔe